Filter the four brands by treatment goal, route, and age group. Then select two or more medications for a side-by-side comparison.
Semaglutide
Class: GLP-1 receptor agonist
Main labeled uses: Type 2 diabetes in adults; selected cardiovascular and kidney risk-reduction indications
Route: Weekly injection or daily tablet
Age: Adults
Diabetes brand. Injection max is 2 mg weekly. Tablets are taken daily on an empty stomach.
Tirzepatide
Class: GIP and GLP-1 receptor agonist
Main labeled uses: Type 2 diabetes
Route: Weekly injection
Age: Adults and children 10 years and older
Diabetes brand. Adult maximum is 15 mg weekly; pediatric maximum is 10 mg weekly.
Semaglutide
Class: GLP-1 receptor agonist
Main labeled uses: Chronic weight management; selected cardiovascular, pediatric obesity, and MASH indications
Route: Weekly injection or daily tablet
Age: Adults; injection also for obesity age 12 and older
Weight-management brand. Injection is also labeled for selected cardiovascular and MASH uses.
Tirzepatide
Class: GIP and GLP-1 receptor agonist
Main labeled uses: Chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity
Route: Weekly injection
Age: Adults
Weight-management brand. Maximum dose is 15 mg weekly.
All four carry a boxed warning concerning thyroid C-cell tumors observed in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Other important risks may include pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney injury, hypoglycemia with insulin or sulfonylureas, and aspiration risk around anesthesia.
Ozempic and Wegovy both contain semaglutide. Mounjaro and Zepbound both contain tirzepatide. Product labeling advises against using these medicines with another product containing the same ingredient or another GLP-1 receptor agonist.
Current through July 18, 2026. Always verify the latest prescribing information.